• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在活体狒狒中绘制脑内抗精神病药物受体图谱。

Mapping brain neuroleptic receptors in the live baboon.

作者信息

Arnett C D, Fowler J S, Wolf A P, Logan J, MacGregor R R

出版信息

Biol Psychiatry. 1984 Oct;19(10):1365-75.

PMID:6083807
Abstract

An experimental strategy for external detection of specific neuroleptic receptors in living brain using positron emission transaxial tomography (PETT) and [11C]spiroperidol was applied to the mapping of brain neuroleptic receptors in the live baboon. A double injection of [11C]spiroperidol with an intervening time interval for carbon-11 decay and an intervening dose of (+)-butaclamol to block specific neuroleptic receptors produced two sets of PETT scans which were subtracted to produce a three-dimensional map of relative regional binding of neuroleptic receptors in the baboon brain. Sixty-five percent of the total radioactivity in the striatum was bound to neuroleptic receptors at 65 min after injection.

摘要

一种利用正电子发射断层扫描(PETT)和[11C]螺哌啶醇对活体大脑中特定抗精神病药物受体进行外部检测的实验策略,被应用于绘制活狒狒大脑中的抗精神病药物受体图谱。对[11C]螺哌啶醇进行两次注射,中间有碳-11衰变的时间间隔,并注射一剂(+)-布他拉莫以阻断特定的抗精神病药物受体,从而产生两组PETT扫描图像,将这两组图像相减,以生成狒狒大脑中抗精神病药物受体相对区域结合的三维图谱。注射后65分钟时,纹状体中65%的总放射性与抗精神病药物受体结合。

相似文献

1
Mapping brain neuroleptic receptors in the live baboon.在活体狒狒中绘制脑内抗精神病药物受体图谱。
Biol Psychiatry. 1984 Oct;19(10):1365-75.
2
Comparison of three 18F-labeled butyrophenone neuroleptic drugs in the baboon using positron emission tomography.使用正电子发射断层扫描技术对狒狒体内三种18F标记的丁酰苯类抗精神病药物进行比较。
J Neurochem. 1985 Mar;44(3):835-44. doi: 10.1111/j.1471-4159.1985.tb12891.x.
3
Specific binding of [11C]spiroperidol in rat brain in vivo.[11C]螺哌啶醇在大鼠脑内的体内特异性结合。
J Neurochem. 1983 Feb;40(2):455-9. doi: 10.1111/j.1471-4159.1983.tb11304.x.
4
[18F]-N-Methylspiroperidol: the radioligand of choice for PETT studies of the dopamine receptor in human brain.[18F]-N-甲基螺哌啶醇:用于人脑多巴胺受体PETT研究的首选放射性配体。
Life Sci. 1985 Apr 8;36(14):1359-66. doi: 10.1016/0024-3205(85)90041-4.
5
No-carrier-added N-(3-[18F]fluoropropyl)spiroperidol: biodistribution in mice and tomographic studies in a baboon.
J Nucl Med. 1987 Jul;28(7):1164-70.
6
Mapping cocaine binding sites in human and baboon brain in vivo.
Synapse. 1989;4(4):371-7. doi: 10.1002/syn.890040412.
7
Kinetic modeling of receptor-ligand binding applied to positron emission tomographic studies with neuroleptic tracers.应用于使用抗精神病药物示踪剂的正电子发射断层扫描研究的受体-配体结合动力学建模。
J Neurochem. 1987 Jan;48(1):73-83. doi: 10.1111/j.1471-4159.1987.tb13129.x.
8
Amphetamine induced decreases in (18F)-N-methylspiroperidol binding in the baboon brain using positron emission tomography (PET).
Synapse. 1991 Apr;7(4):324-7. doi: 10.1002/syn.890070409.
9
Pharmacokinetics and in vivo specificity of [11C]dl-threo-methylphenidate for the presynaptic dopaminergic neuron.[11C]dl-苏式-甲基苯丙胺对突触前多巴胺能神经元的药代动力学及体内特异性
Synapse. 1994 Oct;18(2):152-60. doi: 10.1002/syn.890180207.
10
Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.抗精神病药物对多巴胺和5-羟色胺受体的作用:体外结合和体内更新研究
J Pharmacol Exp Ther. 1981 Dec;219(3):708-14.

引用本文的文献

1
Characteristics of specific in vivo labeling of neuroleptic binding sites with 3-N-[11C]methylspiperone.
Eur J Nucl Med. 1986;11(11):438-43. doi: 10.1007/BF00261006.
2
Evaluation of 75Br-labelled butyrophenone neuroleptics for imaging cerebral dopaminergic receptor areas using positron emission tomography.使用正电子发射断层扫描技术评估75Br标记的丁酰苯类抗精神病药物用于脑多巴胺能受体区域成像的情况。
Eur J Nucl Med. 1986;12(4):211-6. doi: 10.1007/BF00256924.
3
Where have we got to with neuroreceptor mapping of the human brain?我们在人类大脑神经受体图谱方面取得了哪些进展?
Eur J Nucl Med. 1990;16(11):817-35. doi: 10.1007/BF00833018.
4
Uses and limitations of positron emission tomography in clinical pharmacokinetics/dynamics (Part II).
Clin Pharmacokinet. 1992 Apr;22(4):274-83. doi: 10.2165/00003088-199222040-00003.